Zobrazeno 1 - 10 of 17 pro vyhledávání: '"Terry B, Gernsheimer"'
1
Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia
Autor: Anton Ilich, Terry B. Gernsheimer, Darrell J. Triulzi, Heather Herren, Siobhan P. Brown, Lori A. Holle, Andrew T. Lucas, Bas de Laat, Nahed El Kassar, Alisa S. Wolberg, Susanne May, Nigel S. Key
Publikováno v: Blood Advances. 7:900-908
The American Trial Using Tranexamic Acid (TXA) in Thrombocytopenia (A-TREAT, NCT02578901) demonstrated no superiority of TXA over placebo in preventing World Health Organization (WHO) grade 2 or higher bleeding in patients with severe thrombocytopeni
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3669d5a1a25c3b0a7c8fa22ef2096e9f
https://doi.org/10.1182/bloodadvances.2022008255
Zobrazit plný text záznamu
2
Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial
Autor: Terry B. Gernsheimer, Siobhan P. Brown, Darrell J. Triulzi, Nigel S. Key, Nahed El Kassar, Heather Herren, Jacqueline N. Poston, Michael Boyiadzis, Brandi N. Reeves, Subodh Selukar, Monica B. Pagano, Scott Emerson, Susanne May
Publikováno v: Blood. 140:1254-1262
Evidence of the effectiveness of prophylactic use of tranexamic acid (TXA) in thrombocytopenia is lacking. To determine whether TXA safely reduces bleeding incidence in patients undergoing treatment for hematologic malignancies, a randomized, double-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a88ccd07cd2db1bc30ad944f7d6c73c1
https://doi.org/10.1182/blood.2022016308
Zobrazit plný text záznamu
4
Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia
Autor: Eun-Ju Lee, Douglas B. Cines, Howard A. Liebman, Jecko Thachil, Craig M. Kessler, Alexandra Kruse, Michael D. Tarantino, Ashley Ray, Adrian C. Newland, Adam Cuker, Marina Beltrami Moreira, Andrew D. Leavitt, Alfred Ian Lee, Hanny Al-Samkari, Terry B. Gernsheimer, Caroline Kruse, Jennifer DiRaimo, David J. Kuter, James B. Bussel
Publikováno v: Blood
Introduction: Cases of de novo immune thrombocytopenia (ITP), including a fatality following SARS-CoV-2 vaccination in a previously healthy recipient, led to studying its impact in pre-existing ITP. Published reports are limited but suggest that most
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a74ee4ac495baf9e7e8b9f48b13e964
http://europepmc.org/articles/PMC8701617
Zobrazit plný text záznamu
5
Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study
Autor: Debbie Jiang, Adam Cuker, Howard A. Liebman, Hanny Al-Samkari, Matthew Wojdyla, Chelsea Bernheisel, Terry B. Gernsheimer, Scott Kolodny, Michael Vredenburg, Brian Jamieson, Susie Lee
Publikováno v: Blood. 138:1015-1015
BACKGROUND : Thrombopoietin receptor agonists (TPO-RAs) are widely utilized second-line treatments for immune thrombocytopenia (ITP). The TPO-RAs eltrombopag and romiplostim have been FDA approved for over a decade with established efficacy and safet
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d4dd0ade4eeaf09214d1d2741e7bb449
https://doi.org/10.1182/blood-2021-151321
Zobrazit plný text záznamu
7
Durability of Initial Platelet Count Response in Patients Treated with Avatrombopag for Immune Thrombocytopenia (ITP): Post-Hoc Results from a Phase 3 Clinical Study
Autor: Matthew Wojdyla, Terry B. Gernsheimer, Michael Vredenburg, Brian Jamieson, Shivi Jain
Publikováno v: Blood. 136:22-23
Background: The clinical management of ITP has been evolving. Thrombopoietin receptor agonists (TPO-RAs) have become widely utilized as subsequent treatments, and the 2019 ASH guidelines recommend their use over rituximab to achieve a durable respons
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1035ba99252484e050fc5002e76795c0
https://doi.org/10.1182/blood-2020-142764
Zobrazit plný text záznamu
9
Evaluating safety and cost-effectiveness of platelets stored in additive solution (PAS-F) as a hemolysis risk mitigation strategy
Autor: Monica B, Pagano, Brennan L, Katchatag, Shiva, Khoobyari, Mark, Van Gerwen, Nina, Sen, N, Rebecca Haley, Terry B, Gernsheimer, John R, Hess, Ryan A, Metcalf
Publikováno v: Transfusion. 59(4)
Platelet inventory constraints can result in minor ABO incompatibility and possible hemolysis. The aims of this study were to determine the reduction of isoagglutinin in titers of platelets stored in additive solution (PAS) and compare its safety, ef
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e492159eb14561cf29ad7df01e3e8ecf
https://pubmed.ncbi.nlm.nih.gov/30592057
Zobrazit plný text záznamu
10
Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia
Autor: Sherrill J, Slichter, Larry J, Dumont, Jose A, Cancelas, MeLinh, Jones, Terry B, Gernsheimer, Zbigniew M, Szczepiorkowski, Nancy M, Dunbar, Gautham, Prakash, Stephen, Medlin, Neeta, Rugg, Bridget, Kinne, Victor W, Macdonald, Greggory, Housler, Manoj, Valiyaveettil, Peter, Hmel, Janet H, Ransom
Publikováno v: Transfusion. 58(9)
The short dating period of room temperature-stored platelets (PLTs; 5-7 days) limits their availability at far-forward combat facilities and at remote civilian sites in the United States. PLT cryopreservation in 6% DMSO and storage for up to 2 years
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::533c7f945541c6f3b20ea126810cff52
https://pubmed.ncbi.nlm.nih.gov/30204954
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje